Buradasınız

Anasayfa » Content

Yaşlı astımlılarda orta-doz flutikazon ve salmeterolün bronkokonstriksiyonun algılanmasına etkisi

Effect on perception of bronchoconstriction of moderate-dose fluticason plus salmeterol in elderly asthmatics

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
We evaluate the effect of moderate-dose fluticasone plus salmeterol on perception of bronchoconstriction in elderly and in young asthmatics. Twenty-one young asthmatics (aged <60yrs) and 29 elderly asthmatics (>60 yrs ) were studied. The elderly asthmatics were separated into two groups according to the duration of symptoms (late-onset asthma <5 year, early-onset asthma>5 year). 50 patients with moderate asthma were assigned to a 1yr treatment with 250 ug of fluticason propionate plus 50ug salmetorol, twice daily.At entry and after 1 yr, histamine challenge test was performed for each patient. Dyspnea was assessed by modified Borg scale. The Borg score in PEV1 reduction by 20% was determined as perception score 20 (PS20). Results: There was no significant difference between mean PS20 values at entry (1.21 ± 0.18) and after the first year(1.32 ± 0.22) for late onset elderly asthmatics (p=0.7). There was no significant difference between mean PS20 values at entry (1.45 ± 0.14) and after the first year (1.11 ± 0.30) for early onset elderly asthmatics (p=0.2). There was no difference between mean PS20 values at entry (2.27 ± 0.25) and after the first year (2.07 ± 0.29) for young asthmatics (p=0.3). The mean PS20 value of elderly asthmatics at entry (1.31 ± 0.12, 2.27 ± 0.25 p=0001) and after the first year (1.23 ± 0.18,2.07 ± 0.29 p=0.01) was lower than young asthmatics. Conclusion: Öur study suggested that the treatment of moderate-dose fluticasone plus salmeterol did not change perception of bronchoconstriction in elderly asthmatics. Perception of elderly asthmatics at entry and after 1 yr was lower than young asthmatics.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Örta-doz plutikazon ve salmeterol tedavisinin bronkokonstriksiyonun algýlanmasýna etkisinin yaþlý ve genç astýmlýlarda deðerlendirilmesi. Metot: Yirmidokuz yaþlý astýmlý (>60 yaþ) ve 21 genç astýmlý (<60 yaþ) hasta çalýþmaya katýldý. Yaþlý astýmlýlar semptom sürelerine göre iki gruba ayrýldý (geç baþlangýçlý astým< 5 yýl; erken baþlangýçlý astým>5 yýl). Örta persistan astýmlý 50 hasta bir yýl boyunca günde iki defa 250 ug flutikazon propionat ve 50ug salmeterol tedavisi aldý. Her hastaya baþlangýçta ve bir yýl sonra histamin ile bronþ provokasyon testi yapýldý. Nefes darlýðý modifiye Borg skalasý ile deðerlendirildi. Birinci saniye zorlu vital kapasite'de (pEV1) %20'lik bir düþmenin olduðu Borg skoru Algýlama skoru 20 (AS20) olarak saptandý.Sonuçlar: Geç baþlangýçlý yaþlý astýmlýlarda baþlangýç ortalama AS20 deðerleri (1.21 ± 0.18) ile tedavi sonrasý ortalama AS20 deðerleri (1.32 ± 0.22) arasýnda anlamlý fark yoktu (p=0.7). Erken baþlangýçlý yaþlý astýmlýlarda baþlangýç ortalama AS20 deðerleri ile (1.45 ± 0.14) tedavi sonrasý ortalama AS20 deðerleri (1.11 ± 0.30) arasýnda anlamlý fark yoktu (p=0.2). Genç astýmlýlarda baþlangýç ortalama AS20 deðerleri (2.27 ± 0.25) ile tedavi sonrasý ortalama AS20 deðerleri (2.07 ± 0.29) arasýnda anlamlý fark yoktu (p=0.3). Yaþlý astýmlýlarda baþlangýç ortalama AS20 deðerleri (1.31 ± 0.12; 2.27 ± 0.25 p=0.001) ve tedavi sonrasý ortalama AS20 deðerleri (1.23 0.18; 2.07 ± 0.29 p=0.01) genç astýmlýlardan düþüktü. Yorum:Çalýþma orta doz flutikazon ve salmeterol tedavisinin yaþlý ve genç astýmlýlarda bronkokonstriksiyonun algýlanmasýný deðiþtirmediðini düþündürmektedir.Ancak yaþlý astýmlýlarýn baþlangýçtaki ve bir yýl sonraki algýlamalarý genç astýmlýlardan daha düþük bulunmuþtur.
FULL TEXT (PDF): 
PDF icon arastirmax-yasli-astimlilarda-orta-doz-flutikazon-salmeterolun-bronkokonstriksiyonun-algilanmasina-etkisi.pdf
  • 4
10-13
  • Turkish

REFERENCES

References: 

1. Spinhoven P, van Peski-Oosterbaan AS, Van der Does AJ, Willems LN, Sterk PJ. Association ofanxiety with perception ofhistamine induced bronchoconstriction in patients with asthma. Thorax 1997 ;52 (2):149-52.
2. Nguyen BP, Wilson SR, German DF. Patients' perceptions compared with objective ratings ofasthma severity. AnnAllergyAsthmalmmunol 1996 ;77 (3):209-15
3. Bijl-Hofland ID, Cloosterman SG, van Schayck CP, v d Elshout FJ, Akkermans RP, Folgering HT. Perception ofrespiratory sensation assessed by means ofhistamine challenge and threshold loading tests. Chest 2000; 117(4):954-9.
4. Jang AS, Choi IS Increased perception of dyspnea by inhalation of short acting beta2 agonist in patients with asthma ofvarying severity. Ann Allergy Asthma Immunol 2000 ;84(1):79-83.
5. Zach MS, Karner U. Sudden death in asthma. Arch Dis Child 1989 ;64(10):1446-50.
6. Salome CM, Reddel HK, Ware SI, Roberts AM, Jenkins CR, Marks GB ve ark. Effect ofbudesonide on the perception ofinduced airway narrowing in subjects with asthma. AmJ Respir Crit Care Med 2002 ; 165(1):15-21.
7. American Thoracic Society. Standards for diagnosis and care ofpatients with chronic obstructive pulmonary diseases (COPD) and asthma. Am Rev Respir Dis 1987;136:225-244.
8. Foresi A, Mattoli S, Corbo GM, Polidori G, Ciappi G. Comparison ofbronchial response to ultrasonically nebulized distilled water, exercise and methacholine inasthma. Chest 1986;90:822-6.
9. Boulet LP, Leblanc P , Turcotte H. Perception scoring ofinduced bronchoconstriction as an index ofawareness ofasthma symptoms. Chest 1994; 105: 1430-3 .
10. Bijl-Hofland ID, Cloosterman SG, Folgering HT, van Den Elshout Fj, van weel C, van Schayck CP. Inhaled Corticosteroids, combined with Long-acting beta(2)-agonists, improve the perception ofbronchoconstriction in Asthma. Am J Respir Crit Care Med 2001; 164 (5):
S.D.Ü. Tıp pak.
Derg
. 2005:12(4)/10-13
Ekici, Astımlılarda bronkokonstriksiyonun algılanmasına tedavinin etkisi 13
764-9.
11. Weiner P, Berar-Yanay N, Davidovich A, Magadle R, Weiner M.The perception ofdyspnoea in patients with asthma, before and following treatment with inhaled glucocorticosteroids. Respir Med 2000; 94 (2): 161¬5.
12. Boulet LP, Turcotte H, Cartier A, Milot J, Cote J, Malo JL ve ark. Influence ofbeclomethasone and salmeterol ontheperceptionofbronchoconstrication. Chest 1998; 114: 373-9.
13. Roisman GL, Peiffer C, Lachronique JG, Le Cae A, Dusser DJ. Perception ofbronchial obstruction in asthmatic patients: Relationship with bronchial eosinophilic inflammation and epithelial damage an effect ofcorticosteroid treatment. J Clin Invest 1995; 96: 12-21.
14. Ottanelli R, Rosi E, Romagnoli I, Grazzini M, Stendardi L, Duranti R ve ark. Do inhaled corticosteroids affect perception ofdyspnea during bronchoconstriction in asthma?Chest2001; 120(3): 770-7.
15. Higgs CM, Laszlo G. Influence oftreatment with beclomethasone, cromoglycate and theophylline on perception ofbronchoconstriction in patients with bronchial asthma. Clin Sci 1996; 90(3): 227-34.
16. In'tVeen JC, Smits HH, Ravensberg AJ, Hiemstra PS, Sterk PJ, Bel EH. Impaired perception ofdyspnea in patients with severe asthma. Relation to sputum eosinophils. Am J Respir Crit Care Med 1998; 158(4):
1134-41.

Thank you for copying data from http://www.arastirmax.com